DataMeds AI Inc. (MEDS)
MEDS trades on Nasdaq in Health Care, Other Pharmaceuticals. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$3.03
-1.30% on the day
Market cap
$13.7M
Nano cap
Revenue · 2025
$23.3M
+28.7% on 2024
Net income · 2025
-$101.3M
-433.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | MEDS on Nasdaq |
| Sector | Health Care |
| Industry | Other Pharmaceuticals |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0002030763 |
| SEC industry code | Wholesale-Drugs, Proprietaries & Druggists' Sundries |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $23.3M |
| Net income | -$101.3M |
| Operating income | -$93.7M |
| Net margin | -433.9% |
| Operating margin | -401.7% |
| Revenue growth | +28.7% |
| Cash | $43K |
| Total assets | $30.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1/A | 2026-10-09 |
| Latest annual report | 10-K/A | 2026-04-24 |
| Latest quarterly / interim | 10-Q | 2026-08-17 |
| Latest current report | 8-K | 2026-10-13 |
| Latest proxy | PRE 14A | 2026-06-18 |
Source: SEC EDGAR submissions feed, 172 recent filings. All filings on EDGAR.
Peers in Other Pharmaceuticals
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HKPD | Cellyan Biotechnology Co. Ltd | $0.1049 | -1.59% | $5.1M |
| COSM | Cosmos Health Inc. | $0.3829 | +9.53% | $38.5M |
| ESYN | EnerSyn Global Inc. | $2.03 | +3.57% | $60.3M |
| ZSTK | ZeroStack Corp. | $4.37 | 0.00% | $95.4M |
| NUS | Nu Skin Enterprises Inc. | $5.01 | +2.88% | $243.9M |
| HLF | Herbalife Ltd. Common Shares | $14.21 | +4.41% | $1.5B |
| CAH | Cardinal Health Inc. | $239.72 | +0.69% | $55.5B |
| COR | Cencora Inc. | $330.11 | +1.55% | $63.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier